Jingxuan Wei
机构：Nanjing Traditional Chinese Medicine Hospital, Changzhou No.2 People's Hospital, Nanjing Medical University · ORCID：0009-0009-4383-9934
发表论文 2 篇 · 总被引 17 次 · h-index 1
代表论文
- Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China (2024 · International Journal of Clinical Pharmacy · 被引 16)
- Long-term cost-effectiveness of pharmacist-managed hypertension care in China (2025 · BMC Health Services Research · 被引 1)